Close menu




August 6th, 2025 | 07:10 CEST

A bombshell and blatant undervaluation: RENK, Rheinmetall, and Veganz Group

  • Vegan
  • Food
  • Sustainability
  • Defense
Photo credits: pixabay.com

A bombshell at the Veganz Group: In a recent podcast, founder Jan Bredack estimated the value of its subsidiary Mililk at over EUR 80 million, citing "extreme" demand. And new CEO Rayan Tegtmeier also plans to step on the gas and address the "blatant undervaluation" of the foodtech stock. A purchase of Veganz shares appears increasingly compelling. Meanwhile, a bombshell is also looming at Rheinmetall. Analysts are speculating about an upward revision of the Company's forecast. They recommend buying the stock and expect it to soon breakout above the EUR 2,000 mark. Analysts are also optimistic about RENK and are raising their price targets. Incidentally, both defense companies will soon be publishing their quarterly figures.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: RENK AG O.N. | DE000RENK730 , RHEINMETALL AG | DE0007030009 , VEGANZ GROUP AG | DE000A3E5ED2

Table of contents:


    Veganz Group: Revaluation has only just begun

    The Veganz Group is currently valued at less than EUR 40 million. One subsidiary alone could be worth more than twice as much. Investors should therefore not be deterred by the strong share price performance in recent months; the revaluation following the restructuring into a foodtech investment holding company has only just begun. According to both the former and current CEOs, there is still potential for significant price gains.

    According to preliminary figures, Veganz achieved a net profit (EAT) of EUR 23.65 million in the first half of 2025. This corresponds to more than half of the market capitalization and is mainly attributable to the sale of the subsidiary OrbiFarm GmbH. Such "special effects" are likely to occur more frequently in the future.

    Veganz intends to continue to leverage hidden reserves through sales or IPOs. This was clarified by the outgoing founder and CEO, Jan Bredack, in the podcast "Müllers Woche" (https://muellers-woche.podigee.io/5-mw3125), which focuses on German small caps. Bredack will step down from his position and move to OrbiFarm. He will remain a major shareholder in Veganz and emphasized that Veganz will continue to benefit from the positive development of its former subsidiary in the future.

    Bredack described the development at the subsidiary Mililk as extremely promising. Demand is "extreme" – both for the product and among investors. Mililk FoodTech has developed a revolutionary technology for producing food using a patented 2D printing process. Interest is huge, especially in the US and Asia, even though only milk alternatives are currently available. Facilities for milk and coffee creamer could follow soon. Overall, Veganz is addressing markets worth billions. Accordingly, the subsidiary could go public in the future. Bredack considers the previously announced valuation of EUR 80 million to be outdated due to the strong operational development.

    Given these prospects, the incoming Veganz CEO, Rayan Tegtmeier, also considers the share to be massively undervalued: "My goal is to press ahead with the path we have chosen, tap into new growth markets, and get institutional investors excited about Veganz in order to gradually reduce what I believe is the blatant undervaluation of the share."

    Incidentally, the research currently available from mwb (target price EUR 21.50) no longer appears to reflect the latest developments. Anything other than a significant increase in the target price in the next update would be a big surprise.

    Rheinmetall: Price targets rising – Will the forecast soon follow suit?

    Will Rheinmetall shares soon break through the EUR 2,000 mark? The share price is currently trading at around EUR 1,770. In any case, there is a good chance that the sideways movement that has been ongoing since May could soon come to an end. Operations at Germany's largest defense contractor continue to run smoothly. Most recently, the German Armed Forces called up part of the EUR 3.5 billion framework agreement. Rheinmetall is to deliver trucks worth EUR 770 million.

    Analysts at mwb Research believe that this strengthens the visibility for a strong performance in the second half of the year. The order highlights the growing demand for Rheinmetall's modular vehicle platforms across NATO countries. Given the structural increase in defense spending throughout Europe, Rheinmetall is well-positioned to achieve above-average growth thanks to its growing share of equipment sales and increasing presence in the US market. Analysts even anticipate Rheinmetall will raise its forecast in the second half of the year. Against this backdrop, the "Buy" recommendation with a price target of EUR 2,288 is reaffirmed. Rheinmetall remains a key structural growth story in the European defense industry with a CAGR of around 27% through 2030.

    Analysts even anticipate that Rheinmetall will raise its forecast in the coming months. Against this backdrop, the "Buy" recommendation with a price target of EUR 2,288 is reaffirmed. Rheinmetall remains a key structural growth story in the European defense industry, with a projected CAGR of around 27% through 2030.

    RENK: Share price ripe for EUR 84?

    While analysts are likely to raise their price targets for Veganz, experts at RENK have already reacted. Jefferies recently made positive comments about the transmission specialist. An industry study pointed out that it is still not too late to enter the sector, thanks to the supercycle. RENK is well-positioned in the land defense sector. Analysts are expecting further large orders. As a result, the price target has been raised from EUR 60 to EUR 80.

    At Berenberg, the fair value of RENK shares has even climbed from EUR 72 to EUR 84. Analysts have raised their forecast for the entire industry. They pointed to growing momentum in the sector and expect RENK shares to benefit from the quarterly figures published on August 13. RENK shares are currently trading at around EUR 69.


    The revaluation at Veganz appears to have only just begun. The subsidiary Mililk alone seems to be worth more than the stock market currently attributes to the entire group. Those speculating on a sharp correction in defense stocks may be disappointed. Rheinmetall and RENK will publish figures in the coming days. Breakouts from the sideways movement would come as no surprise.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on September 19th, 2025 | 07:00 CEST

    Buy Nordex shares? RENK is betting on vehicle manufacturing! Is Graphano Energy too cheap?

    • Mining
    • graphite
    • Defense
    • Automotive
    • renewableenergies

    No battery works without graphite. At the same time, the raw material is scarce and geopolitically sensitive. This benefits Graphano Energy. Is the stock undervalued? The Company is facing important months ahead. RENK shares are not cheap. But the supercycle in the defense industry is expected to generate strong profits over the coming decade. To handle the anticipated flood of orders, RENK is relying on production standards from the automotive industry. And what about Nordex? Investors are concerned about political headwinds. But analysts are offering reassurance and recommend buying the stock.

    Read

    Commented by André Will-Laudien on September 18th, 2025 | 07:20 CEST

    Margins war and soaring commodity prices! Caution advised on BYD, Mercedes, RENK, and European Lithium

    • Mining
    • Lithium
    • Batteries
    • Commodities
    • Electromobility
    • Defense

    So far, September has turned out to be a month of bliss. It appears that the stock market already underwent its full correction back in April. Investors are still buying high-tech and AI stocks, seemingly unconcerned by valuations of historic proportions. In the wake of this super bull market, automakers BYD and Mercedes have recently suffered significant price corrections. At the same time, the wave of euphoria surrounding defense stock RENK now appears somewhat exaggerated. The rally around critical metals has also driven European Lithium and its US subsidiary Critical Metals significantly higher. With commodity prices recently exploding, however, the rally here is likely only just beginning. We take a closer look at the numbers.

    Read

    Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST

    MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen

    • Hydrogen
    • cleantech
    • Biotechnology
    • Defense

    Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.

    Read